Nanoencapsulation as a Promising Platform for the Delivery of the Morin-Cu(II) Complex: Antibacterial and Anticancer Potential

Nanoencapsulation has emerged as a promising approach for the effective delivery of poorly aqueous soluble compounds. The current study focuses on the preparation of human serum albumin (HSA)-based nanoparticles (NPs) and poly lactic-co-glycolic acid (PLGA)-based nanoparticles for effective delivery of the morin-Cu(II) complex. The NPs were analyzed based on different parameters such as particle size, surface charge, morphology, encapsulation efficiency, and in vitro release properties. The average particle sizes were found to be 214 +/- 6 nm for Mor-Cu-HSA-NPs and 185 +/- 7.5 nm for Mor-Cu-PLGA-NPs. The release of the morin-Cu(II) complex from both the NPs (Mor-Cu-HSA-NPs and Mor-Cu-PLGA-NPs) followed a biphasic behavior, which comprises an early burst release followed by a sustained and controlled release. The resulting NPs also exhibit free radical scavenging activity confirmed by a standard antioxidant assay. The antibacterial activities of the NPs were investigated using a disk diffusion technique, and it was observed that both the NPs showed better antibacterial activity than morin and the morin-Cu(II) complex. The anticancer activities of the prepared NPs were examined on MDA-MB-468 breast cancer cell lines using a cytotoxicity assay, and the mode of cell death was visualized using fluorescence microscopy. Our results revealed that NPs kill the cancer cells with greater efficiency than free morin and the morin-Cu(II) complex. Thus, both HSA-based NPs and PLGA-based NPs can act as promising delivery systems for the morin-Cu(II) complex and can be utilized for further biomedical applications.